

REGENERON PHARMACEUTICALS INC
 Form 4
 October 01, 2008

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
STAHL NEIL

(Last) (First) (Middle)

777 OLD SAW MILL RIVER ROAD

(Street)

TARRYTOWN, NY 10591

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
**REGENERON
 PHARMACEUTICALS INC
 [REGN]**

3. Date of Earliest Transaction (Month/Day/Year)
 09/29/2008

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)
 SVP, Research & Devel Sciences

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)
				(A) or (D)	Price		
Common Stock	09/29/2008		M	25,000	A \$ 8.77	25,350	D
Common Stock	09/29/2008		F	9,417	D \$ 23.28	15,933	D
Common Stock	09/29/2008		F	5,266	D \$ 23.28	10,667	D
Common Stock	09/30/2008		S	200	D \$ 21.66	10,467	D
	09/30/2008		S	200	D	10,267	D

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Common Stock					\$ 22.15		
Common Stock	09/30/2008	S	100	D	\$ 21.75	10,167	D
Common Stock	09/30/2008	S	200	D	\$ 21.79	9,967	D
Common Stock	09/30/2008	S	200	D	\$ 21.7	9,767	D
Common Stock	09/30/2008	S	300	D	\$ 21.74	9,467	D
Common Stock	09/30/2008	S	300	D	\$ 21.73	9,167	D
Common Stock	09/30/2008	S	100	D	\$ 21.64	9,067	D
Common Stock	09/30/2008	S	200	D	\$ 21.72	8,867	D
Common Stock	09/30/2008	S	200	D	\$ 21.8	8,667	D
Common Stock	09/30/2008	S	400	D	\$ 21.77	8,267	D
Common Stock	09/30/2008	S	300	D	\$ 21.81	7,967	D
Common Stock	09/30/2008	S	300	D	\$ 21.69	7,667	D
Common Stock	09/30/2008	S	216	D	\$ 21.68	7,451	D
Common Stock	09/30/2008	S	484	D	\$ 21.67	6,967	D
Common Stock	09/30/2008	S	500	D	\$ 21.65	6,467	D
Common Stock	09/30/2008	S	264	D	\$ 21.57	6,203	D
Common Stock	09/30/2008	S	201	D	\$ 21.63	6,002	D
Common Stock	09/30/2008	S	63	D	\$ 21.51	5,939	D
Common Stock	09/30/2008	S	300	D	\$ 21.59	5,639	D
Common Stock	09/30/2008	S	500	D	\$ 21.66	5,139	D
	09/30/2008	S	100	D		5,039	D

Signatures

/s/**Neil Stahl

09/30/2008

__Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is not applicable in this case.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.